Abu Dhabi integrates genetic testing into Alzheimer’s treatment plans

The updated PGx reports aim to support safer prescribing practices and targeted care.

The Department of Health – Abu Dhabi (DoH), in partnership with M42’s Biogenix Lab, has incorporated APOE E4 genotyping into its pharmacogenomics (PGx) reports to advance precision medicine for Alzheimer’s disease.

The reports allow healthcare providers to customise treatments according to how the body metabolises medications and the biochemical and physiological effects of drugs on the body.

“These insights can be integrated into treatment plans, especially for therapies involving anti-amyloid monoclonal antibodies, to ensure safer and more effective care,” Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at the DoH, said.

When treated with anti-amyloid monoclonal antibodies, patients with two copies of APOE E4 may experience severe side effects, such as brain swelling or bleeding, the DoH said.

By identifying such genetic risks in advance, the updated PGx reports aim to support safer prescribing practices and more targeted care for patients diagnosed with Alzheimer’s disease.